{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:01:28Z","timestamp":1789664488779,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xkme.2026.101439","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:57:52Z","timestamp":1781625472000},"page":"101439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Novel Entity of Renal Toxicity After Combination Chemotherapy: An Onco-Nephrology Kidney Biopsy Teaching Case"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9922-7829","authenticated-orcid":false,"given":"Gian Marco","family":"Berti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Maritati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tondolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Chilotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Fabbrizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianandrea","family":"Pasquinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2303-7845","authenticated-orcid":false,"given":"Gaetano","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisella","family":"Vischini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xkme.2026.101439_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1053\/j.ajkd.2023.04.014","article-title":"Onconephrology: core curriculum 2023","volume":"82","author":"Yarandi","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2026.101439_bib2","first-page":"47","article-title":"Onconephrology: the intersections between the kidney and cancer","volume":"71","author":"Rosner","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.xkme.2026.101439_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/PAP.0000000000000122","article-title":"Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies","volume":"23","author":"Troxell","year":"2016","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.xkme.2026.101439_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000525029","article-title":"Onconephrology: update in anticancer drug-related nephrotoxicity","volume":"147","author":"Garc\u00eda-Carro","year":"2023","journal-title":"Nephron"},{"key":"10.1016\/j.xkme.2026.101439_bib5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0140-6736(11)60242-0","article-title":"The cryoglobulinaemias","volume":"379","author":"Ramos-Casals","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.xkme.2026.101439_bib6","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/art.41003","article-title":"Cryoglobulins today: detection and immunologic characteristics of 1,675 positive samples from 13,439 patients obtained over six years","volume":"71","author":"Kolopp-Sarda","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.xkme.2026.101439_bib7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/clinchem\/hvab195","article-title":"Practical details for the detection and interpretation of cryoglobulins","volume":"68","author":"Kolopp-Sarda","year":"2022","journal-title":"Clin Chem"},{"key":"10.1016\/j.xkme.2026.101439_bib8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.kint.2022.03.030","article-title":"The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis","volume":"102","author":"Javaugue","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2026.101439_bib9","first-page":"13","article-title":"Cryoglobulinemia leading to the diagnosis of low grade serous ovarian carcinoma","volume":"13","author":"Hagopian","year":"2023","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"10.1016\/j.xkme.2026.101439_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer : a randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.xkme.2026.101439_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.xkme.2026.101439_bib12","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2026.101439_bib13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2012.42.5215","article-title":"Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer","volume":"31","author":"Balar","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.xkme.2026.101439_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2023.03.018","article-title":"Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG\/AFU24)","volume":"186","author":"Thibault","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.xkme.2026.101439_bib15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel\u2013carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.xkme.2026.101439_bib16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s10147-021-02103-7","article-title":"Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer","volume":"27","author":"Nasu","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.xkme.2026.101439_bib17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2215\/CJN.00620117","article-title":"Thrombotic microangiopathy and the kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2026.101439_bib18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.xkme.2026.101439_bib19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101439_bib20","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3390\/biomedicines13040767","article-title":"The role of kidney biopsy in Fabry disease","volume":"13","author":"Capelli","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.xkme.2026.101439_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/01913123.2021.2022054","article-title":"Myeloid bodies is not an uncommon ultrastructural finding","volume":"46","author":"Choung","year":"2022","journal-title":"Ultrastruct Pathol"},{"issue":"8","key":"10.1016\/j.xkme.2026.101439_bib22","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/annonc\/mdv136","article-title":"Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)","volume":"26","author":"Launay-Vacher","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T14:14:58Z","timestamp":1786025698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526002013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2590059526002013"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101439","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Novel Entity of Renal Toxicity After Combination Chemotherapy: An Onco-Nephrology Kidney Biopsy Teaching Case","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101439"}}